PRESS RELEASE

14 December 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

Intellectual property (IP) Portfolio addition:

Patent submitted for transformational treatment of non-alcoholic fatty liver disease (NAFLD)

Genflow (LSE: GENF), would like to announce that it has filed a new patent application with the United States Patent and Trademark Office ("USPTO") that relates to variants of Sirtuin-6 ("SIRT6"), and the gene variant's therapeutic uses for the treatment of two disorders involving the liver: non-alcoholic fatty liver disease ("NAFLD"), and non-alcoholic steatohepatitis ("NASH"), an advanced form of NAFLD (the "Application").

Genflow holds the exclusive licence for this application through Genflow Biosciences SRL (the Company's Belgian subsidiary).

NAFLD affects approximately 20% of the general population, meaning this is a significant area for Genflow to be present in the research space with the potential to change the lives of many disorder sufferers. The number of people with NASH, I expected to rise dramatically in future years due to growing obesity rates in developed nations.

In the past decade, large drugmakers including Allergan, Gilead and Novartis, have spent billions of dollars acquiring or licensing medicines designed to treat NASH. 

Dr Eric Leire, Founder and CEO of Genflow, said: "I'm proud of the tremendous progress Genflow has achieved in filing this new patent, and we look forward to adding to the expanding body of knowledge about ageing, liver diseases and bolstering our ever-growing patent portfolio."

IP Portfolio Update: SIRT6 Age-related cases

The international patent application for the use of SIRT6 in the treatment and prevention of age-related diseases has received its first positive review from the Patent Cooperation Treaty Examiner

The PCT Examiner has confirmed the novelty and inventiveness of Genflow's filing which represents the first significant step on the path to the patent, [for which Genflow already has an exclusive license,] being granted.

For further information please contact:

About Genflow

Genflow is a UK-based biotechnology company developing gene therapies designed to target the ageing process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting ageing in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches develop and commercialise therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting ageing in dogs and humans. By treating ageing, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an ageing population.

To learn more visit www.genflowbio.com